Medical experts of Cleveland Clinic, a nonprofit multispecialty academic medical center, announced that they officially started clinical trials of the new vaccine that is designed to prevent triple-negative breast cancer (TNBC) last October 26.
After two decades of research and laboratory studies, the U.S. Food and Drug Administration (FDA) approved the investigational application for the vaccine which allows medical experts to move forward and conduct human trials.
“We are hopeful that this research will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive type of breast cancer,” said G. Thomas Budd, M.D., principal investigator of Cleveland Clinic Taussig Cancer Institute.
The phase-one of the human trials aims to determine the possible side effects and dosage of the vaccine to 18 – 24 patients, who have a history of Triple-Negative Breast Cancer (TNBC) and are currently tumor-free for three years.
Vincent Tuohy, Ph.D., the primary inventor of the vaccine and immunologist at Cleaveland Clinic stated that “our (Cleveland Clinic) research program focuses on developing vaccines that prevent diseases we confront with age, like breast, ovarian and endometrial cancers. If successful, these vaccines have the potential to transform the way we control adult-onset cancers and enhance life expectancy.”
Breast cancer is not a transmissible or infectious disease but according to World Health Organization, there were a total of 7.8 million women alive who were diagnosed with breast cancer in the past 5 years and 685,000 deaths globally.
This viable vaccine to prevent triple-negative breast cancer has the potential to represent a new way to prevent breast cancer and may also apply to other tumor types.
The study is estimated to be completed in September 2022.
Source: https://newsroom.clevelandclinic.org/2021/10/26/cleveland-clinic-launches-first-of-its-kind-preventive-breast-cancer-vaccine-study/, https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Wataalamu wa kliniki ya Cleveland, kituo cha matibabu cha kitaaluma kisicho cha faida, walitangaza kuwa wameanza rasmi majaribio ya kliniki ya chanjo mpya iliyoundwa kuzuia saratani ya matiti ya mara tatu (TNBC) Oktoba 26. Baada ya miongo miwili ya utafiti na majaribio ya maabara, Idara ya Chakula na Dawa ya Marekani (FDA) iliidhinisha maombi ya uchunguzi wa chanjo hiyo ambayo inaruhusu wataalamu wa matibabu kuendelea na kufanya majaribio ya binadamu. "Tuna matumaini kwamba utafiti huu utaongoza kwenye majaribio ya hali ya juu zaidi ili kuamua ufanisi wa chanjo dhidi ya aina hii ya saratani ya matiti yenye nguvu sana, ""alisema G. Thomas Budd, M.D., mtafiti mkuu wa Taasisi ya Saratani ya Cleveland Clinic Taussig." Majaribio ya awamu ya kwanza ya binadamu yana lengo la kuamua athari zinazowezekana na kipimo cha chanjo kwa wagonjwa 18-24 ambao wana historia ya saratani ya matiti ya Triple-Negative (TNBC) na kwa sasa hawana uvimbe kwa miaka mitatu. "Vincent Tuohy, PhD, mvumbuzi mkuu wa chanjo na immunologist katika Kliniki ya Cleveland, alisema: ""Programu yetu ya utafiti (Cleveland Clinic) inazingatia kuendeleza chanjo ambazo huzuia magonjwa tunayoyakabili na umri, kama vile kansa ya matiti, ovari na endometrial." "Hii ni hatua ya kwanza katika kuimarisha uwezo wa watu wazima wa kupambana na saratani na kuongeza muda wa kuishi, ""alisema Daktari mmoja wa afya wa WHO, ambaye amekuwa akitoa taarifa ya vifo vya wanawake milioni 7.8 waliogunduliwa na saratani ya matiti katika miaka mitano iliyopita." Chanjo hii ya kuzuia saratani ya matiti ya triple-negative ina uwezo wa kuwakilisha njia mpya ya kuzuia saratani ya matiti na inaweza pia kutumika kwa aina nyingine za uvimbe. Utafiti huo unakadiriwa kukamilika Septemba 2022. "Mfano: ""Cleveland Clinic"" ni utafiti wa kwanza wa aina yake kuhusu chanjo ya kansa ya matiti, na ""Cleveland Clinic"" ni utafiti wa kwanza wa aina yake kuhusu chanjo ya kansa ya matiti."